Spruce Biosciences, Inc. Common Stock (NASDAQ:SPRB) — Market Cap & Net Worth
Market Cap & Net Worth: Spruce Biosciences, Inc. Common Stock (SPRB)
Spruce Biosciences, Inc. Common Stock (NASDAQ:SPRB) has a market capitalization of $78.59 Million ($78.59 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20111 globally and #4362 in its home market, demonstrating a 6.05% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Spruce Biosciences, Inc. Common Stock's stock price $57.28 by its total outstanding shares 1372043 (1.37 Million). Analyse SPRB cash flow conversion to see how efficiently the company converts income to cash.
Spruce Biosciences, Inc. Common Stock Market Cap History: 2020 to 2026
Spruce Biosciences, Inc. Common Stock's market capitalization history from 2020 to 2026. Data shows growth from $33.35 Million to $78.59 Million (24.41% CAGR).
Index Memberships
Spruce Biosciences, Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #574 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1954 of 3165 |
Weight: Spruce Biosciences, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Spruce Biosciences, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Spruce Biosciences, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.12x
Spruce Biosciences, Inc. Common Stock's market cap is 0.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $1.51 Million | $1.96 Million | -$46.18 Million | 0.77x | N/A |
| 2023 | $4.02 Million | $10.09 Million | -$47.92 Million | 0.40x | N/A |
| 2024 | $576.26K | $4.91 Million | -$53.04 Million | 0.12x | N/A |
Competitor Companies of SPRB by Market Capitalization
Companies near Spruce Biosciences, Inc. Common Stock in the global market cap rankings as of May 4, 2026.
Key companies related to Spruce Biosciences, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Spruce Biosciences, Inc. Common Stock Historical Marketcap From 2020 to 2026
Between 2020 and today, Spruce Biosciences, Inc. Common Stock's market cap moved from $33.35 Million to $ 78.59 Million, with a yearly change of 24.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $78.59 Million | -34.24% |
| 2025 | $119.52 Million | +20640.48% |
| 2024 | $576.26K | -85.67% |
| 2023 | $4.02 Million | +167.09% |
| 2022 | $1.51 Million | -75.40% |
| 2021 | $6.12 Million | -81.65% |
| 2020 | $33.35 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Spruce Biosciences, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $78.59 Million USD |
| MoneyControl | $78.59 Million USD |
| MarketWatch | $78.59 Million USD |
| marketcap.company | $78.59 Million USD |
| Reuters | $78.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Spruce Biosciences, Inc. Common Stock
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating… Read more